Abstract
Oncolytic herpes simplex virus (oHSV) vectors have shown promise in the treatment of patients with recurrent brain tumors although few complete responses have accrued. Impediments to effective therapy include limited vector distribution on delivery, a consequence of injected virion particle trapping in the tumor extracellular matrix (ECM). To enhance virus delivery and spread, we investigated the use of the matrix metalloproteinase-9 (MMP-9) as a means to degrade collagen type IV, a major component of the ECM and basement membranes of gliomas that is absent in normal brain tissue. SK-N-AS neuroblastoma cells were transduced for constitutive, elevated expression of MMP-9, which did not enhance tumor cell migration in vitro or tumor progression in a murine xenograft brain tumor model. MMP-9 expression improved the distribution and infection of oHSV vectors in spheroid model in vitro. Furthermore, MMP9 induced a vector infection over larger areas of brain tumors in vivo. These results suggest that vector delivery and distribution in vivo can be improved by compromising the ECM, potentially enhancing oncolytic efficacy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 2009; 17: 199–207.
McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006; 66: 2509–2513.
Mok W, Boucher Y, Jain RK . Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 2007; 67: 10664–10668.
Zamir EA, Rongish BJ, Little CD . The ECM moves during primitive streak formation—computation of ECM versus cellular motion. PLoS Biol 2008; 6: e247.
Martin MD, Matrisian LM . The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007; 26: 717–724.
Coussens LM, Tinkle CL, Hanahan D, Werb Z . MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103: 481–490.
Bendrik C, Robertson J, Gauldie J, Dabrosin C . Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res 2008; 68: 3405–3412.
Deryugina EI, Zijlstra A, Partridge JJ, Kupriyanova TA, Madsen MA, Papagiannakopoulos T et al. Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res 2005; 65: 10959–10969.
Coussens LM, Fingleton B, Matrisian LM . Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387–2392.
Kondraganti S, Mohanam S, Chintala SK, Kin Y, Jasti SL, Nirmala C et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 2000; 60: 6851–6855.
Lakka SS, Rajan M, Gondi C, Yanamandra N, Chandrasekar N, Jasti SL et al. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 2002; 21: 8011–8019.
Cheng J, Sauthoff H, Huang Y, Kutler DI, Bajwa S, Rom WN et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther 2007; 15: 1982–1990.
Kunapuli P, Kasyapa CS, Hawthorn L, Cowell JK . LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. J Biol Chem 2004; 279: 23151–23157.
Yoshizaki T, Sato H, Furukawa M, Pagano JS . The expression of matrix metalloproteinase 9 is enhanced by Epstein–Barr virus latent membrane protein 1. Proc Natl Acad Sci USA 1998; 95: 3621–3626.
Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV et al. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 2002; 8: 2894–2901.
Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T . Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253: 269–285.
Chintala SK, Rao JK . Invasion of human glioma: role of extracellular matrix proteins. Front Biosci 1996; 1: d324–d339.
Jenkins FJ, Roizman B . Herpes simplex virus 1 recombinants with noninverting genomes frozen in different isomeric arrangements are capable of independent replication. J Virol 1986; 59: 494–499.
Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, Fellows W et al. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2000; 2: 114–120.
Acknowledgements
We thank Antonio Chiocca (Ohio State University) for MGH2, Hideho Okada (University of Pittsburgh) for cell lines, Lucia Mazzacurati and Adriana Forero for technical assistance and Bonnie Reinhart for valuable contributions to the article. This research was supported by NIH Grants nos. NS040923 and CA119298 (to JCG), and by a grant from the Copeland Foundation (to PG).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Hong, CS., Fellows, W., Niranjan, A. et al. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther 17, 1200–1205 (2010). https://doi.org/10.1038/gt.2010.66
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2010.66
Keywords
This article is cited by
-
Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy
Medical Oncology (2017)
-
Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV
Molecular Therapy (2015)
-
Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ΔPK oncolytic activity in melanoma
Gene Therapy (2014)
-
The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy
British Journal of Cancer (2014)
-
Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation
Gene Therapy (2013)